Last $35.15 USD
Change Today +0.05 / 0.14%
Volume 184.2K
NUVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NUVA) Snapshot

Open
$35.14
Previous Close
$35.10
Day High
$35.27
Day Low
$34.66
52 Week High
03/4/14 - $39.89
52 Week Low
09/6/13 - $23.17
Market Cap
1.7B
Average Volume 10 Days
219.1K
EPS TTM
$0.52
Shares Outstanding
47.0M
EX-Date
--
P/E TM
67.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NUVA)

nuvasive inc (NUVA) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NUVA) Details

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product offering includes a minimally disruptive surgical platform, known Maximum Access Surgery (MAS) that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) support; MaXcess, an integrated split-blade retractor system; and various specialized implants. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing consist of allograft (donated human tissue); Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during spine and other surgeries. In addition, the company is developing proprietary total disc replacement devices, which include XL-TDR, a mechanical total disc replacement for lateral lumbar spine applications; and the PCM device for cervical spine applications. It sells its products through independent sales agencies, directly-employed sales shareowners, and distributors to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,358 Employees
Last Reported Date: 03/3/14
Founded in 1997

nuvasive inc (NUVA) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.0K
President and Chief Operating Officer
Total Annual Compensation: $550.0K
President of Global Products & Services
Total Annual Compensation: $520.0K
Executive Vice President of U.S. Sales
Total Annual Compensation: $375.0K
Special Advisor
Total Annual Compensation: $482.5K
Compensation as of Fiscal Year 2013.

nuvasive inc (NUVA) Key Developments

NuVasive, Inc. Announces Executive Changes

NuVasive, Inc. announced that Michael J. Lambert will retire as the company's Chief Financial Officer effective on July 31, 2014 and remain with the company to serve as a special advisor to the Chief Executive Officer through March 15, 2015, and that, in connection with Mr. Lambert's retirement, Quentin Blackford has been promoted to serve as the company's Chief Financial Officer commencing on August 1, 2014. In connection with this transition and also effective August 1, 2014, the company's Board of Directors has appointed Mr. Blackford to serve as the company's Chief Accounting Officer, filling the vacancy created by Michael Lambert's retirement from that role as well.

NuVasive, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reports Asset Impairment Charges for the Second Quarter Ended June 30, 2014; Revises Earnings Guidance for the Full Year 2014

NuVasive, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $190.7 million, a 15.1% increase over the $165.7 million for the second quarter 2013. Loss before income taxes was $2.3 million compared to $6.8 million for the same period of 2013. Net loss was $4.3 million compared to $6.73 million for the same period of 2013. Net loss attributable to the company was $4.09 million or $0.09 per basic and diluted share compared to $6.5 million or $0.15 per basic and diluted share for the same period of 2013. Non-GAAP earnings were $13.6 million or $0.28 per share. For the second quarter, cash flow from operating activities totaled just over $25 million, well ahead of the roughly $8 million in the second quarter of 2013, driven by top line growth and operating margin performance in the quarter. Free cash flow of about $6 million was impacted by about $19 million in capital expenditures in the quarter, most of which was product related. For the six months, the company reported revenue of $368.2 million compared to $325.2 million for the same period of 2013. Loss before income taxes was $35.96 million compared to $6.97 million for the same period of 2013. Consolidated net loss was $22.8 million compared to $6.1 million for the same period of 2013. Net loss attributable to the company was $22.4 million or $0.48 per basic and diluted share compared to $5.6 million or $0.13 per basic and diluted share for the same period of 2013. Net cash provided by operating activities was $48.3 million compared to $32.4 million for the same period of 2013. Purchases of property and equipment were $32.6 million compared to $26.2 million for the same period of 2013. Non-GAAP earnings were $27.9 million or $0.57 per share. For the quarter, the company reported an intangible asset impairment charge of $10.7 million related to the developed technology for the PCM device acquired from Cervitech in 2009, and from investment to support international expansion. The company provided earnings guidance for the full year 2014. For the period, the company expects revenue of approximately $745 million or 9% growth over 2013 revenue of $685 million; increased from approximately $725 million previously. GAAP Loss per Share of approximately $0.38 compared to loss per share of approximately $0.27 previously. Non-GAAP EPS of approximately $1.11 increased from approximately $1.06 previously. Non-GAAP operating margin of approximately 16.5% increased from approximately 16% previously. GAAP effective tax expense of approximately $6.0 million compared to approximately $6.5 million previously. For the full year, the company continued to expect free cash flow will be roughly flat with 2013 results, even in spite of its becoming a significant cash taxpayer 2014. The company continued to anticipate full year 2014 interest and other expense to be approximately $27.5 million, including roughly $14.7 million in noncash interest expense.

NuVasive, Inc. to Report Q2, 2014 Results on Jul 29, 2014

NuVasive, Inc. announced that they will report Q2, 2014 results After-Market on Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUVA:US $35.15 USD +0.05

NUVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $39.80 USD +0.30
Cyberonics Inc $56.02 USD -1.37
Globus Medical Inc $18.14 USD 0.00
Integra LifeSciences Holdings Corp $50.18 USD +0.19
Thoratec Corp $24.90 USD -0.10
View Industry Companies
 

Industry Analysis

NUVA

Industry Average

Valuation NUVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 2.7x
Price/Cash Flow 190.3x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.